Clinical trials: Functional Disorder
Hypertension With Renal Dysfunction
Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.
- Trial name
- NCT01593787
- Testing
- LCZ696
- Where
- 13 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Cataracts
Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL
The objective of this study is to evaluate postoperative visual function in patients implanted bilaterally with the ReSTOR Aspheric Intraocular Lens (IOL).
- Trial name
- NCT00818116
- Testing
- AcrySof ReSTOR Aspheric IOL
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Alcon Research
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Renal Impairment
A Renal Impairment Study for PF-06651600
This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment…
- Trial name
- NCT04037865
- Testing
- PF-06651600
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Meibomian Gland Dysfunction
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
- Trial name
- NCT01633788
- Testing
- AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%
- Where
- 33 sites in United States
- Volunteers
- 232 people
- Sponsor
- Allergan
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Atherosclerosis
Integrated Biomarker And Imaging Study - 2
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
- Trial name
- NCT00268996
- Testing
- SB-480848
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
Radial Shockwave Therapy for Erectile Dysfunction
Objective: To evaluate the efficacy and safety of radial shock waves for the treatment of erectile dysfunction [ED]. Patients and methods: Randomized, double-blind clinical trial.
- Trial name
- NCT03596047
- Testing
- Radial wave therapy
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Boston Medical Group
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
Renal Impairment
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3866 is removed from the…
- Trial name
- NCT03259087
- Testing
- MK-3866
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Erectile Dysfunction
Treatment of Erectile Dysfunction I
Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of…
- Trial name
- NCT01037244
- Testing
- Udenafil
- Where
- 36 sites in United States
- Volunteers
- 618 people
- Sponsor
- Warner Chilcott
Hepatic Insufficiency
A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function
This is a non-randomized, open-label, one treatment, four group, parallel group study to investigate the effect of impaired hepatic function on the pharmacokinetics of entrectinib in participants with different levels of hepatic…
- Trial name
- NCT04226833
- Testing
- entrectinib
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Meibomian Gland Dysfunction
Evaluation of the LipiFlow System With a New Activator
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject.
- Trial name
- NCT04500821
- Testing
- Activator LFD-2100
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Aplastic Anemia
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
Evaluated Exjade efficacy and safety in patients with aplastic anemia and transfusion-dependent iron overload, undergoing treatment programs of immunosuppressive treatment (Cyclosporine A) , in comparison with a group of patients…
- Trial name
- NCT01818726
- Testing
- ICL670, Chelation, No chelation
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Hypothyroidism
Thyroid Function of Pediatric Subjects Following Isovue® Administration
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the…
- Trial name
- NCT03779906
- Testing
- Isovue
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bracco Diagnostics, Inc
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc